Aura Biosciences Investor Relations Material
Latest events
Status Update
Aura Biosciences
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Aura Biosciences Inc
Access all reports
Aura Biosciences Inc. is a biotechnology company focused on developing therapies for cancer treatment. It specializes in the creation of virus-like drug conjugates (VDC) technology, aiming to address tumors with significant unmet medical needs in ocular and urologic oncology. A key development in their portfolio is AU-011, a VDC candidate targeting primary choroidal melanoma. The company also explores the potential of AU-011 for other ocular oncology indications, including choroidal metastases, and is conducting Phase 2 dose-escalation trials. Aura Biosciences is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Key slides for Aura Biosciences Inc
Status Update
Aura Biosciences Inc
Status Update
Aura Biosciences Inc
Latest articles
)
The Rise and Fall of Wirecard
A look inside the Wirecard scandal, which took the company from the prestigious DAX 30 to insolvency through the largest accounting fraud in European history.
16 May 2025
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
Ticker symbol
AURA
Country
🇺🇸 United States